Strategic statement of the Artificial Pancreas Trondheim (APT) research group

The Artificial Pancreas Trondheim (APT) is a research group based at the Norwegian University of Science and Technology (NTNU) and St. Olav's University Hospital. APT was formally initiated in August 2013.

Vision

To eliminate the daily burden and long-term adverse effects of diabetes mellitus. Patients with diabetes mellitus should have the same life expectancy and quality of life as people without this disease.

Primary objective

To create a safe and robust artificial pancreas for patients with diabetes. This artificial pancreas should provide patients with normal or near-normal glucose levels throughout the day without risk of serious hypoglycemia.

Secondary objectives

- To investigate the physiology, develop the technology and perform pre-clinical and clinical trials needed to establish a double intraperitoneal artificial pancreas as a real clinical option.
- To strive for scientific excellence.
- To communicate the research through scientific and public channels while securing Intellectual Property.
- To promote or engage in commercialization of technology developed by the group and its partners. This implies collaboration with industry as appropriate.
- To support and encourage emerging activities that can contribute toward our primary objective.

Other considerations

APT shall seek to cooperate with and to support Norwegian research and especially research at NTNU and St. Olav's Hospital when this is compatible with APT’s objectives.

APT shall as well promote Norwegian research internationally. This includes seeking cooperation with recognized national and international academic and industrial partners.

In this context APT shall ensure that APT/NTNU preserves co-ownership of Intellectual Property that is the result of cooperation.

User groups will be involved in planning, conduction and dissemination of APT’s research.